Griffiths Elizabeth A, Roy Vivek, Alwan Laura, Bachiashvili Kimo, Baird John, Cool Rita, Dinner Shira, Geyer Mark, Glaspy John, Gojo Ivana, Hicks Ashley, Kallam Avyakta, Kidwai Wajih Zaheer, Kloth Dwight D, Kraut Eric H, Landsburg Daniel, Lyman Gary H, Mahajan Anjlee, Miller Ryan, Nachar Victoria, Patel Seema, Patel Shiven, Perez Lia E, Poust Adam, Riaz Fauzia, Rosovsky Rachel, Rugo Hope S, Simon Shayna, Vasu Sumithira, Wadleigh Martha, Westbrook Kelly, Westervelt Peter, Berardi Ryan A, Pluchino Lenora
Roswell Park Comprehensive Cancer Center.
Mayo Clinic Cancer Center.
J Natl Compr Canc Netw. 2022 May;20(5):436-442. doi: 10.6004/jnccn.2022.0026.
The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapy-induced thrombocytopenia (CIT), and chemotherapy-induced anemia (CIA). Management and prevention of these sequelae are an integral part of supportive care for many patients undergoing cancer treatment. The purpose of these guidelines is to operationalize the evaluation, prevention, and treatment of FN, CIT, and CIA in adult patients with nonmyeloid malignancies and to enable the patient and clinician to assess management options for FN, CIT, and CIA in the context of an individual patient's condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for Hematopoietic Growth Factors, with particular emphasis on the incorporation of a newly developed section on CIT.
《NCCN造血生长因子指南》针对发热性中性粒细胞减少症(FN)、化疗引起的血小板减少症(CIT)以及化疗引起的贫血(CIA)的临床管理中生长因子的恰当使用给出了建议。对这些后遗症的管理和预防是许多接受癌症治疗患者支持性护理的重要组成部分。这些指南的目的是将非髓系恶性肿瘤成年患者中FN、CIT和CIA的评估、预防及治疗付诸实践,并使患者和临床医生能够根据个体患者的情况评估FN、CIT和CIA的管理方案。这些《NCCN指南见解》总结了《NCCN造血生长因子指南》近期的重要更新内容,特别强调了新纳入的关于CIT的章节。
J Natl Compr Canc Netw. 2022-5
J Natl Compr Canc Netw. 2020-1
J Natl Compr Canc Netw. 2012-5
Hematol Oncol. 2004-9
J Support Oncol. 2004
Duodecim. 1993
J Natl Compr Canc Netw. 2017-12
Curr Opin Hematol. 2011-1
Blood Res. 2025-5-26
Br J Haematol. 2025-4
Pediatr Blood Cancer. 2025-3